Exosome Diagnostics

What Exosome Diagnostics does

Exosome Diagnostics is a molecular diagnostics company that develops and commercializes blood- and urine-based liquid biopsy tests for cancer, with a primary focus on prostate cancer patient stratification and biopsy decision support. Founded in 2008 and originally headquartered in San Diego (later moving to New York), the company's proprietary technology isolates and analyzes tumor-derived exosomes from bodily fluids, enabling non-invasive detection of cancer-related molecular signals. Its flagship product, the ExoDx Prostate Test (now branded Exo mdx following the MDxHealth acquisition), is supported by Level 1 clinical evidence and offers at-home specimen collection, addressing the clinical challenges of false-negative biopsies and overdiagnosis of indolent prostate cancer. The company operates CLIA-certified and CAP-accredited laboratory facilities, with regulatory licensure extending to New York State and Health Canada.

The business model centers on diagnostic testing services billed through insurance, supplemented by patient financial assistance programs including interest-free payment plans. Exosome Diagnostics serves urologists, oncologists, and men with suspected or diagnosed prostate cancer as primary customers, with a secondary use case in infectious disease testing. Go-to-market relies on physician outreach, clinical education webinars, and direct patient engagement, operating as a B2B2C model where physician recommendation drives test adoption. Pricing is not publicly disclosed but the company emphasizes accessibility through patient assistance infrastructure.

Exosome Diagnostics was historically loss-making, having raised over $112 million in equity financing across multiple rounds (2010-2017) from investors including Forbion Capital Partners, NGN Capital, Qiagen, and Tiger Infrastructure Partners. The company operated as a subsidiary of Bio-Techne Corporation before being acquired by MDxHealth SA in September 2025 for up to $15 million in stock and contingent payments. Following the acquisition, Exosome Diagnostics now operates as a wholly-owned subsidiary within MDxHealth's prostate cancer molecular diagnostics platform, which also includes Confirm mdx, GPS mdx, Select mdx, and Resolve mdx.

Name

Exosome Diagnostics

Legal name

Exosome Diagnostics Inc.

Website

https://exosomedx.com

Company type

Private

Founded year

2008

Operating status

Acquired

Headcount range

51–100 employees

Short description

Exosome Diagnostics develops and commercializes blood- and urine-based liquid biopsy tests for prostate cancer, using proprietary exosome profiling technology to support biopsy decision-making. Founded in 2008 and acquired by MDxHealth in September 2025, the company serves urologists, oncologists, and patients across U.S. CLIA-certified laboratories.

Ownership category

akta.pro rank

Product category

Molecular Cancer Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Liquid biopsy diagnostics
• Exosome-based testing
• Prostate cancer diagnostics
• Molecular diagnostic tests
• Cancer risk stratification

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: MDxHealth generates revenue through laboratory diagnostic testing services. The company offers multiple prostate cancer tests including Exo mdx, Confirm mdx, and GPS mdx. Revenue increased 18% in Q3 2025 to $27.4 million following the acquisition of Exosome Diagnostics. Tests are billed through insurance and include patient assistance programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Exosome Diagnostics develops and commercializes exosome-based liquid biopsy molecular diagnostic tests, principally the ExoDx Prostate Test (now branded Exo mdx), which analyzes tumor-derived exosomes in urine to non-invasively stratify patients for prostate biopsy decision-making. Tests are processed through a CLIA-certified laboratory and supported by Level 1 clinical evidence with at-home specimen collection available.

Product overview

MDxHealth acquired Exosome Diagnostics Inc. in September 2025, adding the Exo mdx (formerly ExoDx) liquid biopsy test to its portfolio of prostate cancer molecular diagnostics. The company's product suite includes tissue-based tests (Confirm mdx, GPS mdx), liquid biopsy tests (Exo mdx), infectious disease tests (Resolve mdx), and Select mdx, forming an integrated diagnostic pathway for urologic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Exo mdx (formerly ExoDx Prostate Test) A liquid biopsy urine test for prostate cancer that uses exosome-based molecular profiling to enhance and simplify patient stratification for prostate biopsy decision-making. Supported by Level 1 Evidence with at-home specimen collection available. Intended for use by urologists, oncologists, and their patients with suspected or diagnosed prostate cancer.

Quantifiable outcome

• Non-invasive liquid biopsy reduces need for invasive tissue biopsies
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• MDxHealth: MDxHealth is the parent acquirer of Exosome Diagnostics and operates an overlapping prostate-cancer molecular diagnostics portfolio (Confirm mdx, GPS mdx, Select mdx, Resolve mdx), making it the most directly comparable commercial platform in urologic molecular diagnostics.
• Guardant Health: Guardant Health is a leading liquid biopsy company offering blood-based NGS tests across multiple cancers. Comparable to Exosome Diagnostics in the liquid biopsy modality and CLIA-laboratory model, though operating at significantly greater scale across indications.
• Exact Sciences (now Exact Sciences Corp.): Exact Sciences operates Oncotype DX and Cologuard and has expanded into liquid biopsy through the Thrive acquisition. Comparable as a molecular diagnostics company with urologic and oncology tests run through a CLIA-certified lab.
• Bio-Techne: Bio-Techne was the prior owner of Exosome Diagnostics and divested it to MDxHealth in September 2025. Bio-Techne supplies exosome research tools and reagents, making it a thematic peer in the exosome-based research and diagnostics ecosystem.

Direct peers

• Natera: Natera offers Signatera, a tumor-informed liquid biopsy MRD test, and runs a CLIA-certified lab serving urology and oncology. Direct competitor to Exosome Diagnostics in the liquid biopsy oncology space with overlapping physician customer base.
• NeoGenomics: NeoGenomics operates a large oncology-focused clinical laboratory with a broad menu of molecular and genetic tests, including liquid biopsy offerings. Comparable in operating model, CLIA lab footprint, and customer base (oncologists, urologists).
• Personal Genome Diagnostics (PGDx): PGDx develops tissue-based and liquid biopsy cancer genomic tests for therapy selection and monitoring. Direct comparable in liquid biopsy oncology diagnostics with a CLIA lab and similar B2B2C go-to-market through oncologists and urologists.

Emerging players

• GRAIL: GRAIL develops Galleri, a multi-cancer early detection blood test using methylation-based cfDNA analysis. Comparable to Exosome Diagnostics as a blood-based cancer screening/early-detection liquid biopsy platform, though focused on multi-cancer rather than prostate specifically.
• Biocept: Biocept offers liquid biopsy tests (Target Selector) for cancer biomarker analysis using ctDNA and CTCs. Comparable as a smaller liquid biopsy oncology diagnostic company with overlapping technology approaches and a similar clinical laboratory operating model.
• Angle plc: Angle plc is developing a liquid biopsy platform using circulating tumor cells (Parsortix) for cancer diagnostics and monitoring. Comparable as an emerging liquid biopsy oncology diagnostics company with proprietary sample-prep technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ExosomeDx
• Facebookfacebook.com/mdxhealth
• LinkedInlinkedin.com/company/exosome-diagnostics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exosome Diagnostics